(MBP) METABOLIC PHARMACEUTICALS LIMITED +3.0c to 64.0c -...

(MBP) METABOLIC PHARMACEUTICALS LIMITED +3.0c to 64.0c - Announced that dosing has finished as planned in the first of two parts of the Phase 1 clinical trial on the company’s pain drug, ACV1. The trial will progress to the second part of dosing in humans this week. Volunteers have so far been administered all the planned single subcutaneous doses of ACV1 escalating in six steps from 5 to 400 micrograms per kg body weight. Based on a favourable, blinded, safety assessment of this first part, ethics approval has been granted to proceed to the second part of the trial, a multiple ascending-dose study. Dosing will start this week at 100 micrograms per kg per day for seven days, with the intention of escalating to 200 and finally 400 micrograms per kg per day for seven days.